Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15813423 | 0.86 | BAZ2B (0.41) | BAZ2BL3MBTL1CYP1A2KMT2AKDM4E | |
| SCHEMBL15814352 | 0.81 | L3MBTL1 (0.37) | BAZ2BL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL610407 | 0.81 | SMN1; SMN2 (0.39) | BAZ2BMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL21961420 | 0.80 | BRD4 (0.46) | BAZ2BMALT1BRD4NFKB1NFKB2 | |
| SCHEMBL6611836 | 0.80 | PLA2G10 (0.43) | BAZ2BL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL6303789 | 0.77 | KMT2A (0.41) | BAZ2BL3MBTL1MALT1MEN1KMT2A | |
| SCHEMBL21961362 | 0.77 | BAZ2B (0.40) | BAZ2BL3MBTL1MALT1BRD4MEN1 | |
| SCHEMBL15813564 | 0.76 | ALDH1A1 (0.35) | BAZ2BL3MBTL1CYP1A2ALDH1A1 | |
| SCHEMBL21960888 | 0.76 | BAZ2B (0.39) | BAZ2BBRD4MEN1KMT2ARXFP1 | |
| SCHEMBL21964580 | 0.76 | BRD4 (0.40) | BAZ2BL3MBTL1MALT1BRD4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878709-B2 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | SCHERING CORPORATION (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063709-A1 | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists | CXCR1, CCR1, ACKR3 | BAZ2B 1081/4885L3MBTL1 4067/4885MALT1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.